UK Reschedules CBD Drug Epidyolex

by Newsfeed


Regulators in the United Kingdom have rescheduled the cannabidiol drug Epidyolex as a Schedule 5 drug, moving the medicine approved to treat severe forms of epilepsy from the much more restrictive Schedule 2 classification. GW Pharmaceuticals, the manufacturer of the medication, announced on Tuesday that the move by the Home Office would take effect in all four constituent nations of the U.K. immediately, with Northern Ireland enacting separate legislation.

“The decision to move Epidyolex to a low level of control is an important one for patients, their families, healthcare professionals, pharmacists and the National Health Service (NHS) as a whole – reducing costs and ensuring the medicine can be dispensed more easily,” said Chris Tovey, the CEO of GW, in a press release. “The extensive pre-clinical and…



Read Full Article Here